Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)

Table 2 Drug-drug and food-drug interactions of DOACs. Adapted from references [20,21,22,23]

Pharmacokinetic interaction		Pharmacodynamic interaction
Can decrease DOAC concentration	Can increase DOAC concentration	Can increase risk of bleeding
Carbamazepine	Amiodarone	Aspirin
Phenobarbital	Clarithromycin	ADP receptor (P2Y₁₂) inhibitors (clopidogrel, prasugrel, ticarelor)
Phenytoin	Cyclosporin A	Fibrinolytics (alteplase, tenecteplase)
Rifampin	Diltiazem	Heparins
St John’s Wort	Dronedarone	NSAIDs
	Grapefruit components (p.e. furanocoumarins)	SNRIs/SSRIs
	Itraconazole	Warfarin
	Ketoconazole
	Nelfinavir
	Quinidine
	Ritonavir
	Tacrolimus
	Verapamil

DOAC Direct oral anticoagulants, NSAIDs non-steroidal anti-inflammatory drugs, SNRIs serotonin norepinephrine reuptake inhibitors, SSRIs selective serotonin reuptake inhibitors

ISSN: 2523-3106